-+ 0.00%
-+ 0.00%
-+ 0.00%

NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION

Reuters·12/08/2025 13:00:02

Please log in to view news